Michel Dahan Net Worth

The estimated Net Worth of Michel Dahan is at least $3.13 Million dollars as of 13 May 2024. Mr. Dahan owns over 34,840 units of Akebia Therapeutics stock worth over $967,812 and over the last 8 years he sold AKBA stock worth over $675,727. In addition, he makes $1,485,250 as Chief Operating Officer and Senior Vice President at Akebia Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Dahan AKBA stock SEC Form 4 insiders trading

Michel has made over 20 trades of the Akebia Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 34,840 units of AKBA stock worth $43,898 on 13 May 2024.

The largest trade he's ever made was selling 95,478 units of Akebia Therapeutics stock on 24 May 2023 worth over $116,483. On average, Michel trades about 8,783 units every 106 days since 2016. As of 13 May 2024 he still owns at least 672,092 units of Akebia Therapeutics stock.

You can see the complete history of Mr. Dahan stock trades at the bottom of the page.

Michel Dahan biography

Michel Dahan serves as Chief Operating Officer, Senior Vice President of the Company. Previously, Mr. Dahan was Akebia’s Senior Vice President, Chief Business Officer from December 2013 to January 2020. Prior to joining Akebia, from 2010 to 2013, Mr. Dahan held various positions at Inspiration Biopharmaceuticals, Inc., a company that filed for protection under Chapter 11 of the U.S. Bankruptcy Code in October 2012 prior to the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013 for total aggregate consideration that could exceed $1 billion, most recently as Vice President, Commercial Development and Strategic Planning, and led global marketing and commercial development in preparation for two global launches. Prior to that, from 2003 to 2010, Mr. Dahan served in various roles for Ipsen, most recently as International Product Director, working on global marketing and strategic planning for their hemophilia franchise, and Strategic Planning Director. Previously, he was in Global Business Development and Licensing for Ipsen. He began his career at BNP Paribas in the investment banking division in 2002. He earned his graduate degree in business administration at HEC Paris (France), his maitrise in mathematics from University Paris VI (France), and he completed an executive education program (PLD) at Harvard Business School.

What is the salary of Michel Dahan?

As the Chief Operating Officer and Senior Vice President of Akebia Therapeutics, the total compensation of Michel Dahan at Akebia Therapeutics is $1,485,250. There are 1 executives at Akebia Therapeutics getting paid more, with John Butler having the highest compensation of $4,316,960.

How old is Michel Dahan?

Michel Dahan is 41, he's been the Chief Operating Officer and Senior Vice President of Akebia Therapeutics since 2020. There are 19 older and no younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.

What's Michel Dahan's mailing address?

Michel's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Akebia Therapeutics

Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter, and Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.

What does Akebia Therapeutics do?

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

Complete history of Mr. Dahan stock trades at Akebia Therapeutics

Akebia Therapeutics executives and stock owners

Akebia Therapeutics executives and other stock owners filed with the SEC include:

• John Butler,
  President, Chief Executive Officer, Director
• Michel Dahan,
  Chief Operating Officer, Senior Vice President
• Nicole Hadas,
  Senior Vice President, Chief Legal Officer, Corporate Secretary
• Dell Faulkingham,
  Senior Vice President, Chief Commercial Officer
• John P. Butler MBA,
  CEO, Pres & Director
• Dr. Steven Keith Burke,
  Sr. VP of R&D and Chief Medical Officer
• Dell Faulkingham,
  Sr. VP & Chief Commercial Officer
• Michel Dahan,
  Sr. VP & COO
• Jason A. Amello,
  Exec. Officer
• Adrian Adams,
  Independent Chairman of the Board
• Michael Rogers,
  Independent Director
• Maxine Gowen,
  Independent Director
• Michael Heffernan,
  Independent Director
• Cynthia Smith,
  Independent Director
• Mark Enyedy,
  Independent Director
• Steven Gilman,
  Independent Director
• Kristen Sheppard,
  Vice President, Investor Relations
• Myles Wolf,
  Independent Director
• Steven Burke,
  Senior Vice President, Chief Medical Officer
• David Spellman,
  Chief Financial Officer, Senior Vice President, Treasurer
• Douglas Jermasek M.B.A.,
  VP of Marketing & Strategy
• Mercedes Carrasco,
  Director of Corp. Communications
• Nicole R. Hadas,
  Sr. VP, Chief Legal Officer & Sec.
• Violetta Cotreau,
  Sr. VP, Chief Accounting Officer & Principal Accounting Officer
• Scott A Canute,
  
• Duane Nash,
  Director
• Ronald C Jr Renaud,
  Director
• Muneer A Satter,
  Director
• Michael D. Clayman,
  Director
• Bradley Maroni,
  SVP & Chief Medical Officer
• Anupam Dalal,
  Director
• Michael S Wyzga,
  Director
• Rita Jain,
  SVP, Chief Medical Officer
• Karen L Tubridy,
  SVP, Chief Development Officer
• Leanne M Zumwalt,
  
• Ron Frieson,
  
• Jodie Pope Morrison,
  
• Robert Shalwitz,
  Chief Medical Officer
• Bioventures Ltd Novartis,
  10% owner
• Holdings A/S Novo,
  10% owner
• Violetta Cotreau,
  SVP, Chief Accounting Officer
• Jason Amello,
  SVP, CFO & Treasurer
• Ellen Snow,
  SVP, CFO and Treasurer
• Nicholas Grund,
  Chief Commercial Officer
• Richard C Malabre,
  Chief Accounting Officer
• Erik Ostrowski,
  SVP, CFO, CBO & Treasurer